Campbell & Co Investment Adviser’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-19,883	Closed	-$493K	–	1187
2024 Q2	$493K	Buy	+19,883	New	+$564K	0.04%	661
2023 Q1	–	Sell	-6,534	Closed	-$290K	–	897
2022 Q4	$290K	Sell	6,534 -9,007	-58%	-$379K	0.07%	564
2022 Q3	$663K	Buy	+15,541	New	+$796K	0.15%	226
2020 Q1	–	Sell	-2,651	Closed	-$548K	–	220
2019 Q4	$548K	Buy	+2,651	New	+$490K	0.17%	208

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Campbell & Co Investment Adviser's LKFT Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2024, closing a stake of 19,883 shares — an estimated $493K sold.

Campbell & Co Investment Adviser first reported a position in LKFT in Q4 2019 and held it in 4 quarters. The position peaked at $663K in Q3 2022. 79 funds tracked by Wall St. Rank hold LKFT as of Q3 2024.

Campbell & Co Investment Adviser reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 19,883 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2024, an estimated $493K.
Campbell & Co Investment Adviser first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and held it in 4 quarters.
Campbell & Co Investment Adviser's Lakefront Biotherapeutics American Depositary Shares position peaked at $663K in Q3 2022.
79 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.